Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma
Abstract. The international, randomized phase 3 HD15 trial established 6xeBEACOPP as standard therapy for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) within the German Hodgkin Study Group (GHSG). We performed a follow-up analysis to assess long-term efficacy and safety of this...
Main Authors: | Andreas Engert, Helen Goergen, Jana Markova, Thomas Pabst, Julia Meissner, Josée M. Zijlstra, Zdenek Král, Dennis A. Eichenauer, Martin Soekler, Richard Greil, Stefanie Kreissl, Ruth Scheuvens, Hans Eich, Carsten Kobe, Markus Dietlein, Harald Stein, Michael Fuchs, Volker Diehl, Peter Borchmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2017-12-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000005 |
Similar Items
-
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
by: Peter Borchmann, et al.
Published: (2018-06-01) -
Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
by: Jesko Momotow, et al.
Published: (2021-03-01) -
THERAPY-RELATED MYELOID NEOPLASMS IN PATIENTS TREATED FOR HODGKIN LYMPHOMA
by: Dennis A Eichenauer, et al.
Published: (2011-10-01) -
Suicide in European Hodgkin Lymphoma Patients
by: Austin I. Kim, et al.
Published: (2019-04-01) -
Expanded use of rituximab in the management of non-Hodgkin lymphoma
by: Dennis A Eichenauer, et al.
Published: (2009-07-01)